Emerging therapies in pheochromocytoma and paraganglioma: immune checkpoint inhibitors in the starting blocks

HIGHLIGHTS

• who: Giuseppe Fanciulli et al. from the NET Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari-Endocrine Unit, AOU Sassari, Sassari, Italy have published the research work: Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks, in the Journal: (JOURNAL) of 23/Nov/2020
• what: The aim of this review is to summarize and discuss available data on efficacy and Aim of theofStudy safety current FDA-approved immune checkpoint inhibitors (ICIs) in patients with The trial aims at investigating MTD/maximum administered dose, and dose confirmation in Phase . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.